NK-One Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-04-27.
NK-One Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on April 27, 2026. The filing reports $290K sold. Its industry group is Biotechnology. It names Michael Shine (Chief Executive Officer and President), Marco Pappagallo (Secretary) (SEC Form D, April 27, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like NK-One Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-04-27 · the record
Pitching, partnering or investing alongside them? See who really runs and owns NK-One Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind NK-One Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in Pennsylvania, filed within 90 days of this one, largest first.
Get an email when NK-One Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when NK-One Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch NK-One Therapeutics, Inc. →Get the full cited report on NK-One Therapeutics, Inc.
What the filing shows about NK-One Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on NK-One Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives NK-One Therapeutics, Inc.'s address as 526 Park Ridge Drive, Wayne, PA 19087.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on NK-One Therapeutics, Inc. See pricing
NK-One Therapeutics, Inc. is a registered filer with the SEC (CIK 2127553) and has filed since 2026-04-27. 1 filing is on record, the latest on 2026-04-27.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
NK-One Therapeutics, Inc.'s Form D of 2026-04-27 names Michael Shine and Marco Pappagallo as its officers, directors or promoters.
Its new offerings report $290K sold across 1 offering, as its own filings state.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $290K, on the same scale — one filing against the whole group's total, so it sits low by construction.
On the filing as: Executive Officer, Director.
Michael Shine is named as Chief Executive Officer and President on the Form D that NK-One Therapeutics, Inc. filed with the SEC on 27 April 2026, one of 2 people that filing names.
On the filing as: Executive Officer, Director.
Marco Pappagallo is named as Secretary on the Form D that NK-One Therapeutics, Inc. filed with the SEC on 27 April 2026, one of 2 people that filing names.
2 people named on the filing — 2 holding an executive role.
Named as of the 2026-04-27 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
What the filing shows about NK-One Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on NK-One Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NK-One Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist NK-One Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind NK-One Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for NK-One Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Philadelphia
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/nk-one-therapeutics-inc-form-d-26000001